We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+29.49%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$102M
AUM Growth
-$13.6M
Cap. Flow
+$12.8M
Cap. Flow %
12.5%
Top 10 Hldgs %
84.98%
Holding
22
New
7
Increased
4
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$11.8M
2
INCY icon
Incyte
INCY
+$7.45M
3
BPMC
Blueprint Medicines
BPMC
+$6.79M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.7M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.94M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.3M
2
SPHS
Sophiris Bio, Inc.
SPHS
+$800K
3
ZGNX
Zogenix, Inc.
ZGNX
+$571K
4
KURA icon
Kura Oncology
KURA
+$42.3K

Sector Composition

Rank Sector Weight
1 Healthcare 88.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.2M 15.87%
757,935
-1,265,297
-63% -$28.3M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$12.7M 12.46%
705,159
+391,533
+125% +$6.79M
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$12.2M 11.96%
+416,879
New +$11.8M
CPXX
4
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$9.21M 9.02%
+835,408
New +$2.74M
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$8.2M 8.02%
233,600
+73,600
+46% +$2.47M
INCY icon
6
Incyte
INCY
$24.2B
$7.25M 7.09%
+100,000
New +$7.45M
NGNE icon
7
Neurogene
NGNE
$656M
$7.23M 7.08%
41,001
+530
+1% +$103K
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.6B
$5.77M 5.65%
+70,000
New +$5.7M
ARDM
9
DELISTED
Aradigm Corp Common Stock
ARDM
$4.89M 4.79%
1,101,513
– –
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.69B
$3.12M 3.05%
+234,220
New +$2.94M
KURA icon
11
Kura Oncology
KURA
$800M
$2.62M 2.56%
645,685
-8,910
-1% -$42.3K
AVXS
12
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.27M 2.22%
+83,276
New +$1.82M
VTAE
13
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.09M 2.04%
315,025
+64,755
+26% +$589K
AKTX
14
Akari Therapeutics
AKTX
$13.8M
$1.96M 1.92%
175
– –
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.58M 1.55%
707
– –
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.56M 1.53%
3,111
– –
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
$1.55M 1.52%
168,000
-57,000
-25% -$571K
SPHS
18
DELISTED
Sophiris Bio, Inc.
SPHS
$786K 0.77%
546,088
-453,912
-45% -$800K
NVET
19
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$511K 0.5%
154,840
– –
ALDX icon
20
Aldeyra Therapeutics
ALDX
$92.9M
$265K 0.26%
63,146
– –
EPIX
21
DELISTED
ESSA Pharma
EPIX
$91K 0.09%
1,405
– –
ACHV icon
22
Achieve Life Sciences
ACHV
$659M
$60K 0.06%
+40
New +$65.2K

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Boxer Capital held 22 positions worth $102M, down 12% from $116M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Boxer Capital deployed $12.8M of net new capital in Q1 2016, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was BeOne Medicines Ltd: 416,879 shares worth $12.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $28.3M trimmed.

  • Boxer Capital's largest Q1 2016 buy was BeOne Medicines Ltd: 416,879 shares worth $12.2M.
  • Boxer Capital added most to Blueprint Medicines in Q1 2016, an estimated $6.79M increase.
  • Boxer Capital's biggest Q1 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $28.3M.
  • Boxer Capital's ten largest holdings make up 85% of its $102M portfolio in Q1 2016.
  • Boxer Capital opened 7 new positions and closed 0 in Q1 2016.
  • Boxer Capital's portfolio value fell 12% quarter-over-quarter to $102M.

Based on Boxer Capital's 13F filing for Q1 2016, filed 16 May 2016.